Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Kathleen M. Schmainda PhD

Kathleen M. Schmainda PhD

Professor

Institution: Medical College of Wisconsin
Department: Radiology
Division: Research

Member of the Cancer Center
Member of the Neuroscience Research Center


Publications

  • Spiral Perfusion Imaging With Consecutive Echoes (SPICE™) for the Simultaneous Mapping of DSC- and DCE-MRI Parameters in Brain Tumor Patients: Theory and Initial Feasibility. (Paulson ES, Prah DE, Schmainda KM) Tomography 2016 Dec;2(4):295-307 PMID: 28090589 PMCID: PMC5226659 01/17/2017
  • Magnetic Resonance Imaging-Based Radiomic Profiles Predict Patient Prognosis in Newly Diagnosed Glioblastoma Before Therapy. (McGarry SD, Hurrell SL, Kaczmarowski AL, Cochran EJ, Connelly J, Rand SD, Schmainda KM, LaViolette PS) Tomography 2016 Sep;2(3):223-228 PMID: 27774518 PMCID: PMC5074084 10/25/2016
  • Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma. (Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS) AJNR Am J Neuroradiol 2016 Dec;37(12):2201-2208 PMID: 27492073 PMCID: PMC5161572 08/06/2016
  • ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI. (Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, Prah M, Schmainda KM, Mintz A, Kostakoglu L, Eikman EA, Ellingson BM, Ratai EM, Sorensen AG, Barboriak DP, Mankoff DA, ACRIN 6684 Trial Group) Clin Cancer Res 2016 Oct 15;22(20):5079-5086 PMID: 27185374 PMCID: PMC5065740 05/18/2016
  • Location of brain tumor intersecting white matter tracts predicts patient prognosis. (Mickevicius NJ, Carle AB, Bluemel T, Santarriaga S, Schloemer F, Shumate D, Connelly J, Schmainda KM, LaViolette PS) J Neurooncol 2015 Nov;125(2):393-400 PMID: 26376654 09/18/2015
  • Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment. (Boxerman JL, Schmainda KM, Zhang Z, Barboriak DP) Neuro Oncol 2015 Nov;17(11):1538-9 PMID: 26361983 PMCID: PMC4648309 09/13/2015
  • Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma. (Prah MA, Stufflebeam SM, Paulson ES, Kalpathy-Cramer J, Gerstner ER, Batchelor TT, Barboriak DP, Rosen BR, Schmainda KM) AJNR Am J Neuroradiol 2015 Sep;36(9):1654-61 PMID: 26066626 PMCID: PMC4567906 06/13/2015
  • Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients. (Jafari-Khouzani K, Emblem KE, Kalpathy-Cramer J, Bjørnerud A, Vangel MG, Gerstner ER, Schmainda KM, Paynabar K, Wu O, Wen PY, Batchelor T, Rosen B, Stufflebeam SM) Transl Oncol 2015 Jun;8(3):137-46 PMID: 26055170 PMCID: PMC4486737 06/10/2015
  • Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. (Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL) Neuro Oncol 2015 Aug;17(8):1148-56 PMID: 25646027 PMCID: PMC4490871 02/04/2015
  • Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma. (LaViolette PS, Mickevicius NJ, Cochran EJ, Rand SD, Connelly J, Bovi JA, Malkin MG, Mueller WM, Schmainda KM) Neuro Oncol 2014 Dec;16(12):1599-606 PMID: 25059209 PMCID: PMC4232087 07/26/2014
  • Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics. (Heroux MS, Chesnik MA, Halligan BD, Al-Gizawiy M, Connelly JM, Mueller WM, Rand SD, Cochran EJ, LaViolette PS, Malkin MG, Schmainda KM, Mirza SP) Physiol Genomics 2014 Jul 01;46(13):467-81 PMID: 24803679 PMCID: PMC4587597 05/08/2014
  • The effect of low b-values on the intravoxel incoherent motion derived pseudodiffusion parameter in liver. (Cohen AD, Schieke MC, Hohenwalter MD, Schmainda KM) Magn Reson Med 2015 Jan;73(1):306-11 PMID: 24478175 PMCID: PMC4317387 01/31/2014
  • Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. (Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman RG, Mueller W, Malkin MG) Neuro Oncol 2014 Jun;16(6):880-8 PMID: 24431219 PMCID: PMC4022214 01/17/2014
  • Effect of contrast leakage on the detection of abnormal brain tumor vasculature in high-grade glioma. (LaViolette PS, Daun MK, Paulson ES, Schmainda KM) J Neurooncol 2014 Feb;116(3):543-9 PMID: 24293201 PMCID: PMC4316680 12/03/2013
  • Diffusion-weighted MRI as a biomarker for treatment response in glioma. (Schmainda KM) CNS Oncol 2012 Nov;1(2):169-80 PMID: 23936625 PMCID: PMC3734866 08/13/2013
  • Multiphasic modification of intrinsic functional connectivity of the rat brain during increasing levels of propofol. (Liu X, Pillay S, Li R, Vizuete JA, Pechman KR, Schmainda KM, Hudetz AG) Neuroimage 2013 Dec;83:581-92 PMID: 23851326 PMCID: PMC3815996 07/16/2013
  • The effect of pulse sequence parameters and contrast agent dose on percentage signal recovery in DSC-MRI: implications for clinical applications. (Boxerman JL, Paulson ES, Prah MA, Schmainda KM) AJNR Am J Neuroradiol 2013 Jul;34(7):1364-9 PMID: 23413249 PMCID: PMC4316677 02/16/2013
  • Effects of perfusion on diffusion changes in human brain tumors. (Cohen AD, LaViolette PS, Prah M, Connelly J, Malkin MG, Rand SD, Mueller WM, Schmainda KM) J Magn Reson Imaging 2013 Oct;38(4):868-75 PMID: 23389889 PMCID: PMC3735792 02/08/2013
  • Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. (LaViolette PS, Cohen AD, Prah MA, Rand SD, Connelly J, Malkin MG, Mueller WM, Schmainda KM) Neuro Oncol 2013 Apr;15(4):442-50 PMID: 23382287 PMCID: PMC3607265 02/06/2013
  • The Role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard. (Boxerman JL, Prah DE, Paulson ES, Machan JT, Bedekar D, Schmainda KM) AJNR Am J Neuroradiol 2012 Jun;33(6):1081-7 PMID: 22322605 PMCID: PMC4331024 02/11/2012
  • Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume. (Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Schmainda KM) Magn Reson Med 2012 Oct;68(4):1266-72 PMID: 22213469 PMCID: PMC3323703 01/04/2012
  • Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. (Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB) Neuro Oncol 2011 Oct;13(10):1151-61 PMID: 21856685 PMCID: PMC3177656 08/23/2011
  • Characterization of bevacizumab dose response relationship in U87 brain tumors using magnetic resonance imaging measures of enhancing tumor volume and relative cerebral blood volume. (Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Hoffmann RG, Schmainda KM) J Neurooncol 2011 Nov;105(2):233-9 PMID: 21533524 PMCID: PMC4323180 05/03/2011
  • Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI. (Ellingson BM, LaViolette PS, Rand SD, Malkin MG, Connelly JM, Mueller WM, Prost RW, Schmainda KM) Magn Reson Med 2011 Apr;65(4):1131-43 PMID: 21413079 PMCID: PMC3065939 03/18/2011
  • 3D visualization of subdural electrode shift as measured at craniotomy reopening. (LaViolette PS, Rand SD, Ellingson BM, Raghavan M, Lew SM, Schmainda KM, Mueller W) Epilepsy Res 2011 Mar;94(1-2):102-9 PMID: 21334178 PMCID: PMC4329774 02/22/2011
  • Multimodality imaging of abnormal vascular perfusion and morphology in preclinical 9L gliosarcoma model. (Darpolor MM, Molthen RC, Schmainda KM) PLoS One 2011 Jan 31;6(1):e16621 PMID: 21305001 PMCID: PMC3031600 02/10/2011
  • Three-dimensional visualization of subdural electrodes for presurgical planning. (LaViolette PS, Rand SD, Raghavan M, Ellingson BM, Schmainda KM, Mueller W) Neurosurgery 2011 Mar;68(1 Suppl Operative):152-60; discussion 160-1 PMID: 21206319 PMCID: PMC4339031 01/06/2011
  • Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter- and intrapatient comparisons. (Bedekar D, Jensen T, Schmainda KM) Magn Reson Med 2010 Sep;64(3):907-13 PMID: 20806381 PMCID: PMC4323176 09/02/2010
  • Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. (Ellingson BM, Malkin MG, Rand SD, LaViolette PS, Connelly JM, Mueller WM, Schmainda KM) J Neurooncol 2011 Mar;102(1):95-103 PMID: 20798977 PMCID: PMC3033973 08/28/2010
  • A simple method for rectified noise floor suppression: Phase-corrected real data reconstruction with application to diffusion-weighted imaging. (Prah DE, Paulson ES, Nencka AS, Schmainda KM) Magn Reson Med 2010 Aug;64(2):418-29 PMID: 20665786 PMCID: PMC4321728 07/29/2010
  • Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. (Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, Bedekar DP, Schmainda KM) J Magn Reson Imaging 2010 Mar;31(3):538-48 PMID: 20187195 PMCID: PMC2903058 02/27/2010
  • Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri. (Ellingson BM, Rand SD, Malkin MG, Schmainda KM) J Neurooncol 2010 May;97(3):419-23 PMID: 19813078 PMCID: PMC2956408 10/09/2009
  • Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. (Hu LS, Baxter LC, Pinnaduwage DS, Paine TL, Karis JP, Feuerstein BG, Schmainda KM, Dueck AC, Debbins J, Smith KA, Nakaji P, Eschbacher JM, Coons SW, Heiserman JE) AJNR Am J Neuroradiol 2010 Jan;31(1):40-8 PMID: 19749223 PMCID: PMC4323177 09/15/2009
  • Computer-aided detection of brain tumor invasion using multiparametric MRI. (Jensen TR, Schmainda KM) J Magn Reson Imaging 2009 Sep;30(3):481-9 PMID: 19711398 PMCID: PMC4321878 08/28/2009
  • Diffusion heterogeneity tensor MRI (?-Dti): mathematics and initial applications in spinal cord regeneration after trauma - biomed 2009. (Ellington BM, Schmit BD, Gourab K, Sieber-Blum M, Hu YF, Schmainda KM) Biomed Sci Instrum 2009;45:167-72 PMID: 19369758 04/17/2009
  • Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. (Paulson ES, Schmainda KM) Radiology 2008 Nov;249(2):601-13 PMID: 18780827 PMCID: PMC2657863 09/11/2008
  • A novel technique for modeling susceptibility-based contrast mechanisms for arbitrary microvascular geometries: the finite perturber method. (Pathak AP, Ward BD, Schmainda KM) Neuroimage 2008 Apr 15;40(3):1130-43 PMID: 18308587 PMCID: PMC2408763 03/01/2008
  • Assessment of the morphological and functional effects of the anti-angiogenic agent SU11657 on 9L gliosarcoma vasculature using dynamic susceptibility contrast MRI. (Quarles CC, Schmainda KM) Magn Reson Med 2007 Apr;57(4):680-7 PMID: 17390352 03/29/2007
  • Water diffusion heterogeneity index in the human brain is insensitive to the orientation of applied magnetic field gradients. (Bennett KM, Hyde JS, Schmainda KM) Magn Reson Med 2006 Aug;56(2):235-9 PMID: 16929466 08/25/2006
  • Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. (Boxerman JL, Schmainda KM, Weisskoff RM) AJNR Am J Neuroradiol 2006 Apr;27(4):859-67 PMID: 16611779 04/14/2006
  • Improving the reliability of obtaining tumor hemodynamic parameters in the presence of contrast agent extravasation. (Quarles CC, Ward BD, Schmainda KM) Magn Reson Med 2005 Jun;53(6):1307-16 PMID: 15906288 05/21/2005
  • Dexamethasone normalizes brain tumor hemodynamics as indicated by dynamic susceptibility contrast MRI perfusion parameters. (Quarles CC, Krouwer HG, Rand SD, Schmainda KM) Technol Cancer Res Treat 2005 Jun;4(3):245-9 PMID: 15896079 05/18/2005
  • Intravoxel distribution of DWI decay rates reveals C6 glioma invasion in rat brain. (Bennett KM, Hyde JS, Rand SD, Bennett R, Krouwer HG, Rebro KJ, Schmainda KM) Magn Reson Med 2004 Nov;52(5):994-1004 PMID: 15508160 10/28/2004
  • Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. (Schmainda KM, Rand SD, Joseph AM, Lund R, Ward BD, Pathak AP, Ulmer JL, Badruddoja MA, Krouwer HG) AJNR Am J Neuroradiol 2004 Oct;25(9):1524-32 PMID: 15502131 10/27/2004
  • Lesion-induced pseudo-dominance at functional magnetic resonance imaging: implications for preoperative assessments. (Ulmer JL, Hacein-Bey L, Mathews VP, Mueller WM, DeYoe EA, Prost RW, Meyer GA, Krouwer HG, Schmainda KM) Neurosurgery 2004 Sep;55(3):569-79; discussion 580-1 PMID: 15335424 09/01/2004
  • Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. (Badruddoja MA, Krouwer HG, Rand SD, Rebro KJ, Pathak AP, Schmainda KM) Neuro Oncol 2003 Oct;5(4):235-43 PMID: 14565159 PMCID: PMC1920679 10/21/2003
  • Characterization of continuously distributed cortical water diffusion rates with a stretched-exponential model. (Bennett KM, Schmainda KM, Bennett RT, Rowe DB, Lu H, Hyde JS) Magn Reson Med 2003 Oct;50(4):727-34 PMID: 14523958 10/03/2003
  • The effect of brain tumor angiogenesis on the in vivo relationship between the gradient-echo relaxation rate change (DeltaR2*) and contrast agent (MION) dose. (Pathak AP, Rand SD, Schmainda KM) J Magn Reson Imaging 2003 Oct;18(4):397-403 PMID: 14508775 09/26/2003
  • Noninvasive assessment of neoplastic angiogenesis: the role of magnetic resonance imaging. (Abu-Hajir M, Rand SD, Krouwer HG, Schmainda KM) Semin Thromb Hemost 2003 Jun;29(3):309-15 PMID: 12888935 07/31/2003
  • Gene transfer establishes primacy of striated vs. smooth muscle sarcoglycan complex in limb-girdle muscular dystrophy. (Durbeej M, Sawatzki SM, Barresi R, Schmainda KM, Allamand V, Michele DE, Campbell KP) Proc Natl Acad Sci U S A 2003 Jul 22;100(15):8910-5 PMID: 12851463 PMCID: PMC166412 07/10/2003
  • Water exchange and inflow affect the accuracy of T1-GRE blood volume measurements: implications for the evaluation of tumor angiogenesis. (Kim YR, Rebro KJ, Schmainda KM) Magn Reson Med 2002 Jun;47(6):1110-20 PMID: 12111957 07/12/2002
  • MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis. (Pathak AP, Schmainda KM, Ward BD, Linderman JR, Rebro KJ, Greene AS) Magn Reson Med 2001 Oct;46(4):735-47 PMID: 11590650 10/09/2001
  • Last update: 02/08/2017
    jenkins-FCD Prod-62 d4cab8cdea3c4a9de9a7ab88569aac11edfb5130